| Product NDC: | 51672-1323 |
| Proprietary Name: | Ciclopirox |
| Non Proprietary Name: | Ciclopirox |
| Active Ingredient(s): | 7.7 mg/mL & nbsp; Ciclopirox |
| Administration Route(s): | TOPICAL |
| Dosage Form(s): | SUSPENSION |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 51672-1323 |
| Labeler Name: | Taro Pharmaceuticals U.S.A., Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA077092 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20050810 |
| Package NDC: | 51672-1323-4 |
| Package Description: | 1 BOTTLE in 1 CARTON (51672-1323-4) > 60 mL in 1 BOTTLE |
| NDC Code | 51672-1323-4 |
| Proprietary Name | Ciclopirox |
| Package Description | 1 BOTTLE in 1 CARTON (51672-1323-4) > 60 mL in 1 BOTTLE |
| Product NDC | 51672-1323 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Ciclopirox |
| Dosage Form Name | SUSPENSION |
| Route Name | TOPICAL |
| Start Marketing Date | 20050810 |
| Marketing Category Name | ANDA |
| Labeler Name | Taro Pharmaceuticals U.S.A., Inc. |
| Substance Name | CICLOPIROX OLAMINE |
| Strength Number | 7.7 |
| Strength Unit | mg/mL |
| Pharmaceutical Classes | Decreased DNA Replication [PE],Decreased Protein Synthesis [PE],Decreased RNA Replication [PE],Protein Synthesis Inhibitors [MoA] |